Eupraxia Pharmaceuticals Price Target Cut by Analysts

HC Wainwright reduces EPRX price target to $11 from $12

Mar. 17, 2026 at 12:24pm

Got story updates? Submit your updates here. ›

Eupraxia Pharmaceuticals (NASDAQ:EPRX) had its price target lowered by stock analysts at HC Wainwright from $12.00 to $11.00 in a research report issued on Tuesday. The firm maintained a 'buy' rating on the stock, indicating a potential upside of 48.85% from the previous closing price.

Why it matters

This price target reduction by a major analyst firm could impact investor sentiment and trading activity around Eupraxia Pharmaceuticals' stock. As a clinical-stage biotech company, its share price is heavily dependent on progress with its drug development pipeline, so analyst views carry significant weight.

The details

In the report, HC Wainwright cited ongoing challenges and risks facing Eupraxia as the reason for the lower price target. Several other analysts have also recently weighed in on the stock, with Wall Street Zen downgrading it to a 'sell' rating and Weiss Ratings reaffirming a 'sell (d-)' rating. However, Cantor Fitzgerald and Lifesci Capital have maintained bullish stances, with Cantor Fitzgerald raising its price target to $19 and Lifesci Capital upgrading the stock to a 'strong-buy' rating.

  • The price target cut was issued on March 17, 2026.

The players

HC Wainwright

A stock research and investment banking firm that covers Eupraxia Pharmaceuticals.

Eupraxia Pharmaceuticals

A clinical-stage biotechnology company focused on developing novel therapies for autoimmune and inflammatory diseases.

Wall Street Zen

An equity research firm that downgraded Eupraxia Pharmaceuticals to a 'sell' rating.

Cantor Fitzgerald

An investment bank that raised its price target on Eupraxia Pharmaceuticals to $19.

Lifesci Capital

An investment research firm that upgraded Eupraxia Pharmaceuticals to a 'strong-buy' rating.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

This price target reduction by HC Wainwright reflects ongoing challenges and risks facing Eupraxia Pharmaceuticals as a clinical-stage biotech company. However, the mixed analyst views on the stock highlight the uncertainty and volatility inherent in this sector, underscoring the need for investors to closely monitor developments in Eupraxia's drug pipeline and overall business performance.